Nanobots: The current scenario

IF 5.5 2区 医学 Q1 HEMATOLOGY Critical reviews in oncology/hematology Pub Date : 2025-02-08 DOI:10.1016/j.critrevonc.2025.104652
Dr. Shalini Gupta, Dr. Arushi Tomar, Dr. Lakshmi Manohar, Dr. Payal Panwar
{"title":"Nanobots: The current scenario","authors":"Dr. Shalini Gupta,&nbsp;Dr. Arushi Tomar,&nbsp;Dr. Lakshmi Manohar,&nbsp;Dr. Payal Panwar","doi":"10.1016/j.critrevonc.2025.104652","DOIUrl":null,"url":null,"abstract":"<div><div>The detection and treatment of cancer could be completely transformed by the application of nanotechnology. New nanoscale targeting methods have emerged as a result of advancements in materials science and protein engineering, giving cancer patients new hope. Only a small number of nanocarriers have been approved for clinical usage in targeting cancer cells, despite the fact that many have been licensed for human studies. We examine a few of the approved formulations in this study and talk about the difficulties in transferring laboratory results to clinical settings. This review emphasises the inherent challenges in cancer therapy as well as the different nanocarriers and chemicals that can be used for specific tumour targeting. Future advancements in cancer detection and therapy could be facilitated by nanotechnology, but still the area remains vast and more clinical as well as laboratory trails are the need of the hour to overcome the present barriers and align the discovery of the potential application of nanobots from a mere lab work to a full-fledged clinical and translational work.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"208 ","pages":"Article 104652"},"PeriodicalIF":5.5000,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S104084282500040X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The detection and treatment of cancer could be completely transformed by the application of nanotechnology. New nanoscale targeting methods have emerged as a result of advancements in materials science and protein engineering, giving cancer patients new hope. Only a small number of nanocarriers have been approved for clinical usage in targeting cancer cells, despite the fact that many have been licensed for human studies. We examine a few of the approved formulations in this study and talk about the difficulties in transferring laboratory results to clinical settings. This review emphasises the inherent challenges in cancer therapy as well as the different nanocarriers and chemicals that can be used for specific tumour targeting. Future advancements in cancer detection and therapy could be facilitated by nanotechnology, but still the area remains vast and more clinical as well as laboratory trails are the need of the hour to overcome the present barriers and align the discovery of the potential application of nanobots from a mere lab work to a full-fledged clinical and translational work.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.00
自引率
3.20%
发文量
213
审稿时长
55 days
期刊介绍: Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.
期刊最新文献
Editorial Board The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative review Molecular oncology of iodine refractory thyroid cancer current therapies and perspective Advances of artificial intelligence in clinical application and scientific research of neuro-oncology: Current knowledge and future perspectives Chimeric antigen receptor T cell immunotherapy for gynecological malignancies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1